All In Biotech

Drug Trial Radar · NCT07634744

A Phase IIa Study in Primary IgA Nephropathy Patients

A Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of XH-S003 in Patients With Primary IgA Nephropathy

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Dec 31, 2024

Primary completion

Apr 23, 2026

Study completion Apr 23, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patients with primary IgA nephropathy

Conditions

  • IgA Nephropathy

Interventions

  • XH-S003 CapsuleDrug

    Oral, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. UPCRTime frame: Baseline and Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.